Month: September 2026

ICG Enterprise Trust plc (the “Company”)

16 September 2026

Transaction in Own Shares

The Company announces that on 15 September 2026 it bought back 5,549 of its own shares under the long-term buyback programme, to be held as treasury shares, at an average price of 1400 pence per share.

Further details are set out below:

• Number of shares held as treasury shares following settlement of this purchase: 3,179,951
• Total shares in issue excluding treasury shares following settlement of this purchase: 60,374,241

The Company has bought back these shares under the authority granted by shareholders at its Annual General Meeting in June 2026, which permits the Company to repurchase a maximum of 14.99% of its ordinary shares. The actual number of shares repurchased by the Company will depend on market conditions. This authority lasts until the next shareholder authority granted (expected to be at the Annual General Meeting in 2027), or until expressly revoked by shareholders.

No maximum consideration payable has been determined by the Company, but the Company is unable to pay a price for any shares pursuant to the buyback which would equate to a premium to the net asset value. It is the Company’s current intention to hold any shares bought back in treasury.

The Company has instructed Numis Securities Limited (trading for these purposes as Deutsche Numis) as its broker in respect of its buyback transactions. This arrangement is in accordance with the UKLA Listing Rules and the Company’s general authority to repurchase shares.

Analyst / Investor enquiries:

Chris Hunt
Shareholder Relations, ICG
+44 (0) 20 3545 2020

Andrew Lewis
Company Secretary, ICG
+44 (0) 20 3545 1344

Media:

Clare Glynn
Corporate Communications, ICG
+44 (0) 20 3545 1395

Lochem, 16 September 2026

ForFarmers expands operations in Poland with acquisition of STW SA

ForFarmers, through its Polish subsidiary Tasomix, has entered into an agreement to acquire 100% of the shares in STW SA, an animal feed producer based in Sokołów Podlaski (eastern Poland). The transaction is in line with the growth strategy of ForFarmers to further strengthen their position in the Polish market, particularly in the poultry, ruminant and swine sectors. The acquisition is subject to approval by the Polish competition authority. The transaction is expected to be finalized at the beginning of 2027.

STW SA: modern feed production site
STW SA was founded in 2016 and is owned by the Leszczyński family. The company operates a modern feed production facility in Eastern Poland and is also active in feed logistics and poultry farming. Following recent investments, the annual feed production capacity has increased to approximately 270,000 tonnes. With a workforce of 76 employees, STW SA has developed substantial expertise and technical know-how in feed formulation.

Stronger position in an attractive growth market
Tasomix, which has been operating in Poland for over 35 years and has been part of ForFarmers since 2018, has been collaborating with STW SA for several years. As part of this partnership, STW SA already manufactures for Tasomix. 

“This acquisition, in which we are acquiring the production site and the product and customer portfolio, is a good addition to Tasomix’s activities in eastern Poland and creates scope for further growth. In addition, we will benefit from STW SA’s knowledge and experience and realise efficiency gains in production and logistics. This will enable us to serve our customers even better and further strengthen our position in the Polish market,” says Paweł Świerkula, Managing Director of Tasomix.

Michał Leszczyński, CEO of STW SA: “We are convinced that this acquisition lays a strong foundation for further growth and development. The combination of local commitment with the scale, knowledge and expertise of ForFarmers/Tasomix creates new opportunities for customers and employees. We look forward to working together to make this next step a success.”

Scope of the transaction
The transaction comprises the feed business with its modern production facility, excluding the feed logistics and poultry farming of the Leszczyński family.  Tasomix and  Leszczyński family intend to further strengthen their cooperation, particularly in the areas of logistics and the supply of feed to the poultry farms of the Leszczyński family.

This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Note to the editor:
Media: Ilse Niehof-Duivelshof, T: +31 (0)573 28 88 00
Investors: Floor van Maaren, T +31 (0)573 28 88 00

Company profile
ForFarmers N.V. (ForFarmers) is a leading player in Europe, offering complete feed solutions for (organic) livestock farming and with annual sales of over 10 million tonnes of animal feed. With its mission statement ‘For the Future of Farming’, ForFarmers is committed to future-proof farming and making the agricultural sector even more sustainable. The company has production operations in the Netherlands (where the head office is located), Germany, Poland and the United Kingdom, and exports to various countries within and outside Europe. ForFarmers employs around 3,000 people and is listed on Euronext Amsterdam.

ForFarmers N.V., PO-Box 91, 7240 AB Lochem
T: +31 (0)573 28 88 00 – info@forfarmers.eu – www.forfarmersgroup.eu/en

FORWARD-LOOKING STATEMENTS

This document contains forward-looking statements that include ForFarmers’ regulatory capital and liquidity positions under certain specified scenarios. In addition, forward-looking statements may include, without limitation, statements containing words such as ”intends”, ”expects”, ”takes into account”, ”aims at”, ”has the plan”, ”estimates” and words of similar purport. These statements concern or may affect future matters, such as ForFarmers’ future financial results, business plans and current strategies. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results and performance to differ materially from the expected future results or performance implicitly or explicitly contained in forward-looking statements. Factors that may cause, or contribute to, differences in current expectations include, but are not limited to: developments in legislation, technology, taxation, case law and regulations, fluctuations in stock prices, legal proceedings, investigations by regulators, competitive conditions, and general economic conditions. These and other factors, risks and uncertainties that may affect any forward-looking statement or the actual results of ForFarmers are discussed in the latest published annual report. The forward-looking statements contained in this document relate solely to statements as of the date of this document, and ForFarmers assumes no obligation or responsibility to update the forward-looking statements contained in this announcement, whether in connection with new information, future events or otherwise, unless ForFarmers is required by law to do so.

Company presentation

BW Offshore is presenting today at Pareto Securities’ annual Energy Conference. Please see the attached presentation.

For further information, please contact:
Ståle Andreassen, CFO, +47 91 71 86 55
IR@bwoffshore.com   www.bwoffshore.com

About BW Offshore:

BW Offshore engineers innovative floating production solutions. The Company has a fleet of FPSOs and floating wind solutions. By leveraging four decades of offshore operations and project execution, the Company creates tailored offshore energy solutions for evolving markets worldwide. BW Offshore has around 900 employees and is publicly listed on the Oslo stock exchange.

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Attachment

• Company presentation

Press Release

Data on Nicox’s NCX 470 to be presented at AAOpt Annual Meeting 2026

September 16, 2026 – release at 7:30 am Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that key scientific data on NCX 470 will be presented at the upcoming American Academy of Optometry (AAOpt) Annual Meeting 2026 (September 30 – October 3, 2026, Anaheim, CA, U.S.). Nicox will also be participating in several key ophthalmology, financial and industry conferences in the second half of 2026. “NCX 470 is an investigational new drug for the reduction of intraocular pressure which has recently completed a multi-region Phase 3 clinical program. AAOpt provides an important opportunity to share the data from these trials directly with the optometrist community, which plays a central role in the diagnosis and ongoing management of glaucoma. This forum enables us to engage directly with optometrists and place the clinical findings for NCX 470 in the context of glaucoma management in everyday practice.” said Siobhan Garbutt, VP and Head of Clinical Development of Nicox. Data from Nicox’s clinical trials, Denali, Whistler and Mont Blanc has already been presented at a number of key ophthalmology conferences. All publications can be found on our website. AAOpt 2026 Annual Meeting – September 30 to October 3, 2026, Anaheim, CA, U.S.  Presentation Details   Title: The Denali Trial U.S. Subgroup: A Randomized Trial Comparing NCX 470 0.1% and Latanoprost 0.005% for Open-Angle Glaucoma or Ocular Hypertension Type: Paper Presentation Date: Thursday, October 1, 2026 at 08:15 am (local time) Presenter: Nora Cothran, OD, Fellow of the American Academy of Optometry Title: Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution (Nitric Oxide-Donating Bimatoprost): A Double-Masked, Placebo-Controlled, Phase 3b Clinical Trial Type: Poster Presentation – Board #162 Date: Thursday, October 1, 2026 at 4:30 pm (local time) Presenter: Siobhan Garbutt, PhD H2 Conference Attendance American Academy of Ophthalmology (AAO) – October 9-12, 2026 – New Orleans, Louisiana – United-States Investor Access – October 6-7, 2026 – Paris, France Members of the Nicox team will be available for one-on-one meetings at these events. If you wish to set up a meeting, please contact us at communications@nicox.com.

About NCX 470

NCX 470 is a novel nitric oxide (NO)-donating bimatoprost eye drop that leverages the potent intraocular pressure (IOP)-lowering effects of NO and prostaglandin analogs (PGAs). NCX 470 incorporates Nicox’s proprietary NO-donating research platform and bimatoprost in a single molecule. NCX 470 is designed to release bimatoprost and NO into the eye to lower IOP by two different pathways in patients with open-angle glaucoma or ocular hypertension. NO is a well-known small, naturally occurring signalling molecule that plays a key role in the regulation of IOP through activation of soluble guanylate cyclase (sGC). NO brings additional IOP-lowering efficacy by enhancing aqueous humor drainage from the eye via a different mechanism of action to that of PGAs. NCX 470 has completed two Phase 3 clinical trials designed to fulfil the regulatory requirements for safety and efficacy to support NDA submissions in the U.S. and China, Mont Blanc and Denali. Both trials were positive and met the efficacy endpoints necessary for submission of a New Drug Application in the United States and China. NDAs for NCX 470 have been submitted in the U.S. and China. NCX 470 is an investigational product and has not yet been approved by the FDA.

About Nicox

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.  Nicox’s lead late-stage development program is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world.  Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos.  Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories.  Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX). For more information www.nicox.com

Analyst coverage
H.C. Wainwright & Co        Yi Chen           New York, U.S.
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Contacts
Nicox Gavin Spencer Chief Executive Officer T +33 (0)4 97 24 53 00 communications@nicox.com
Disclaimer
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2024” and in section 4 of the “Rapport semestriel 2025” which are available on Nicox’s website (www.nicox.com). Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.
Nicox S.A. Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, France T +33 (0)4 97 24 53 00

Attachment

• EN_AAOpt Annual Meeting NCX470 Data presentation_FINAL